Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.

摘要: OBJECTIVES Definitive concurrent chemoradiotherapy is the standard treatment for stage III non-small cell lung cancer (NSCLC). Previous studies showed that tumor size and its metabolic activity are predictors of outcome. We investigated whether there new prognostic factors survival NSCLC after definitive chemoradiotherapy. PATIENTS AND METHODS A total 57 consecutive patients treated with their IIIA (n=22) IIIB (n=35) (AJCC 7th edition) unresectable were identified. 43 (75.4%) had positron emission tomography integrated computed (PET-CT) scan performed at diagnosis subsequently reviewed analyzed. Prognosticators progression-free (PFS), distant metastasis-free (DMFS), overall (OS) RESULTS The median PFS, DMFS, OS 14.1, 12.6, 37.8 months, respectively, a follow-up 41.5 months. PFS advantage was demonstrated in versus (median 38.6 vs. 13.5 mo, P=0.020), N-stage N0-N2 N3 16.7 8.1 P<0.001), planning target volume (PTV) <500 ≥500 cm 23.6 11.3 P=0.008), maximum standardized uptake value (SUVmax) nodes <8 ≥8 16.1 10.7 P=0.048). DMFS noted those PTV<500 PTV≥500 13.0 P=0.045) SUVmax 8.0 P=0.050). revealed 56.5 22.7 P=0.013) (42.3 12.8 P=0.009). Multivariate analysis only factor OS. Metabolic lesion glycolysis not factors. CONCLUSIONS our study. PET-CT time useful stratifying into favorable unfavorable groups